All In Biotech

Drug Trial Radar · NCT07719491

Study of GS-0415 and How It Works in People With HIV

A First-in-Human Phase 1b, Single-Blind, Placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate Safety and Pharmacokinetics of GS-0415 in People With HIV-1 Who Are Virologically Suppressed on Antiretroviral Treatment

Last checked: Nov 20, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

112

Planned (sponsor's estimate)

Start

Jul 22, 2026

Primary completion

Aug 2029

Study completion Aug 2029

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and intravenous (IV) GS-0415 in people with HIV-1 (PWH) on antiretroviral treatment. The primary objectives of this study are to evaluate the safety and tolerability of escalating, single and multiple subcutaneous (SC) and intravenous (IV) doses of GS-0415, administered in PWH who are virologically suppressed on antiretroviral therapy (ART) and to evaluate the pharmacokinetics (PK) of GS-0415.

Conditions

  • HIV -1 Infection

Interventions

  • GS-0415Drug

    Administered SC or IV

  • GS-0415 PlaceboDrug

    Administered SC or IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs)Time frame: First dose date up to 99 days
  2. Percentage of Participants Experiencing Clinical Laboratory AbnormalitiesTime frame: First dose date up to 99 days
  3. Serum Pharmacokinetic (PK) Parameter (After Single Ascending Dose (SAD)): AUCinf of GS-0145Time frame: Up to 43 days
  4. Serum PK Parameters (SAD): Cmax of GS-0145Time frame: Up to 43 days
  5. Serum PK Parameters Multiple Ascending Dose (MAD): Dose 1 and Dose 5: AUCtau of GS-0145Time frame: Up to 99 days
  6. Serum PK Parameters MAD: Dose 1 and Dose 5: Cmax of GS-0145Time frame: Up to 99 days

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Floridian Clinical Research, LLC

    Miami Lakes, Florida · Recruiting

  • Triple O Research Institute, P.A.

    West Palm Beach, Florida · Recruiting

  • Emory University Hospital Midtown Infectious Disease Clinic

    Atlanta, Georgia · Recruiting

  • Centricity Research CPU - Georgia

    Columbus, Georgia · Recruiting

  • Indiana CTSI Clinical Research Center

    Indianapolis, Indiana · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • PPD Development, LP

    Las Vegas, Nevada · Recruiting

  • St. Michaels Medical Center

    Newark, New Jersey · Not yet recruiting

  • Jacobi Medical Center

    The Bronx, New York · Recruiting

  • Duke Early Phase Clinical Research Unit

    Durham, North Carolina · Recruiting

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina · Recruiting

  • University of Cincinnati College of Medicine

    Cincinnati, Ohio · Recruiting

  • The Ohio State University Medical Center Infectious Diseases Clinic

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.